Literature DB >> 33632126

Diagnostic accuracy assessment of molecular prediction model for the risk of NAFLD based on MRI-PDFF diagnosed Chinese Han population.

Qing Zhang1, Yueli Zhu1, Wanjiang Yu1, Zhipeng Xu1, Zhenzhen Zhao2, Shousheng Liu2, Yongning Xin3, Kuirong Lv4.   

Abstract

BACKGROUND: Several molecular prediction models based on the clinical parameters had been constructed to predict and diagnosis the risk of NAFLD, but the accuracy of these molecular prediction models remains need to be verified based on the most accurate NAFLD diagnostic method. The aim of this study was to verify the accuracy of three molecular prediction models Fatty liver index (FLI), NAFLD liver fat score system (NAFLD LFS), and Liver fat (%) in the prediction and diagnosis of NAFLD in MRI-PDFF diagnosed Chinese Han population. PATIENTS AND METHODS: MRI-PDFF was used to diagnose the hepatic steatosis of all the subjects. Information such as name, age, lifestyle, and major medical histories were collected and the clinical parameters were measured by the standard clinical laboratory techniques. The cut-off values of each model for the risk of NAFLD were calculated based on the MRI-PDFF results. All data were analyzed using the statistical analysis software SPSS 23.0.
RESULTS: A total of 169 subjects were recruited with the matched sex and age. The ROC curves of FLI, NAFLD LFS, and Liver fat (%) models were plotted based on the results of MRI-PDFF. We founded that the accuracy of FLI, NAFLD LFS, and Liver fat (%) models for the prediction and diagnosis of NAFLD were comparative available in Chinese Han population as well as the validity of them in other ethnics and regions.
CONCLUSIONS: The molecular prediction models FLI, NAFLD LFS, and Liver fat (%) were comparative available for the prediction and diagnosis of NAFLD in Chinese Han population. MRI-PDFF could be used as the golden standard to develop the new molecular prediction models for the prediction and diagnosis of NAFLD.

Entities:  

Keywords:  MRI-PDFF; Molecular prediction model; Non-alcoholic fatty liver disease

Mesh:

Year:  2021        PMID: 33632126      PMCID: PMC7908643          DOI: 10.1186/s12876-021-01675-y

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  35 in total

1.  Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease.

Authors:  Anna Alisi; Massimo Pinzani; Valerio Nobili
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

2.  Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease.

Authors:  Susanne Bonekamp; An Tang; Arian Mashhood; Tanya Wolfson; Christopher Changchien; Michael S Middleton; Lisa Clark; Anthony Gamst; Rohit Loomba; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-06       Impact factor: 4.813

Review 3.  Obesity in the critically ill: a narrative review.

Authors:  Miet Schetz; Audrey De Jong; Adam M Deane; Wilfried Druml; Pleun Hemelaar; Paolo Pelosi; Peter Pickkers; Annika Reintam-Blaser; Jason Roberts; Yasser Sakr; Samir Jaber
Journal:  Intensive Care Med       Date:  2019-03-19       Impact factor: 17.440

Review 4.  Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.

Authors:  Jiulian Gu; Shousheng Liu; Shuixian Du; Qing Zhang; Jianhan Xiao; Quanjiang Dong; Yongning Xin
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

5.  Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom.

Authors:  Diego Hernando; Samir D Sharma; Mounes Aliyari Ghasabeh; Bret D Alvis; Sandeep S Arora; Gavin Hamilton; Li Pan; Jean M Shaffer; Keitaro Sofue; Nikolaus M Szeverenyi; E Brian Welch; Qing Yuan; Mustafa R Bashir; Ihab R Kamel; Mark J Rice; Claude B Sirlin; Takeshi Yokoo; Scott B Reeder
Journal:  Magn Reson Med       Date:  2016-04-15       Impact factor: 4.668

Review 6.  Nonalcoholic fatty liver disease: a systematic review.

Authors:  Mary E Rinella
Journal:  JAMA       Date:  2015-06-09       Impact factor: 56.272

7.  Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.

Authors:  Vanessa El Kamari; Corrilynn O Hileman; Pierre M Gholam; Manjusha Kulkarni; Nicholas Funderburg; Grace A McComsey
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

Review 8.  Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

Authors:  Eduardo Vilar-Gomez; Naga Chalasani
Journal:  J Hepatol       Date:  2017-12-02       Impact factor: 25.083

9.  Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.

Authors:  Michael S Middleton; Mark L Van Natta; Elhamy R Heba; Adina Alazraki; Andrew T Trout; Prakash Masand; Elizabeth M Brunt; David E Kleiner; Edward Doo; James Tonascia; Joel E Lavine; Wei Shen; Gavin Hamilton; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

Review 10.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

View more
  2 in total

1.  Relationship of circulating total bilirubin, UDP-glucuronosyltransferases 1A1 and the development of non-alcoholic fatty liver disease: a cross-sectional study.

Authors:  Xuefeng Ma; Xu Zheng; Shousheng Liu; Likun Zhuang; Mengke Wang; Yifen Wang; Yongning Xin; Shiying Xuan
Journal:  BMC Gastroenterol       Date:  2022-01-05       Impact factor: 3.067

2.  Liver biomarkers, genetic and lifestyle risk factors in relation to risk of cardiovascular disease in Chinese.

Authors:  Xinyu Wang; Si Cheng; Jun Lv; Canqing Yu; Yu Guo; Pei Pei; Ling Yang; Iona Y Millwood; Robin Walters; Yiping Chen; Huaidong Du; Haiping Duan; Simon Gilbert; Daniel Avery; Junshi Chen; Yuanjie Pang; Zhengming Chen; Liming Li
Journal:  Front Cardiovasc Med       Date:  2022-08-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.